Proposed Cardiovascular Risk Assessment Algorithm Using High-Sensitivity C-Reactive Protein and Lipid Screening
Key result
High-sensitivity C-reactive protein strongly predicts future cardiovascular events across multiple cohorts, with the highest levels increasing risk up to 4.4-fold (95% CI, 2.2-8.9).
Why the study?
Does high-sensitivity C-reactive protein (hs-CRP) screening predict future cardiovascular events and improve risk assessment compared to standard lipid screening?
Population
Apparently healthy men and women, and elderly individuals with subclinical cardiovascular disease
Comparison
High-sensitivity C-reactive protein screening vs Standard lipid screening
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May refine risk stratification beyond lipids; leaves open whether screening improves outcomes in trials.
Structured PICO
Does high-sensitivity C-reactive protein (hs-CRP) screening predict future cardiovascular events and improve risk assessment compared to standard lipid screening?
P
Population
Apparently healthy men and women, and elderly individuals with subclinical cardiovascular disease (based on multiple prospective epidemiologic cohorts from the United States and Europe)
I
Intervention
High-sensitivity C-reactive protein (hs-CRP) screening
C
Comparator
Standard lipid screening
O
Outcome
Future coronary and cardiovascular events (including mortality, stroke, myocardial infarction, and peripheral vascular disease)hard clinical
High-sensitivity CRP is a strong predictor of future cardiovascular events across multiple populations, supporting its potential inclusion in cardiovascular risk assessment algorithms alongside standard lipid screening.
Cite This Study
Rifai et al. (2001) conducted a review in Cardiovascular risk. High-sensitivity C-reactive protein (hs-CRP) screening vs. Low hs-CRP concentrations / standard lipid screening was evaluated on Future coronary and cardiovascular events. High-sensitivity C-reactive protein strongly predicts future cardiovascular events across multiple cohorts, with the highest levels increasing risk up to 4.4-fold (95% CI, 2.2-8.9).